Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Akebia Therapeutics, Inc. (AKBA)
Price$0.9747Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $211.7M | $294.6M | $335.0M | $207.7M | $181.2M | $1.5M | $0 | $0 | — | — |
| Gross profit | $196.7M | $97.0M | $120.5M | $206.9M | $61.0M | −$1.8M | $189.7M | $200.0M | — | — | — | — | — | — |
| Gross margin | 83.29% | 60.56% | 61.90% | 70.74% | 28.81% | −0.62% | 56.62% | 96.26% | — | — | — | — | — | — |
| Research & development | $62.4M | $37.7M | $6.4M | $7.6M | $147.9M | $218.5M | $323.0M | $291.0M | $230.9M | $115.8M | $43.0M | $23.3M | $8.9M | $5.6M |
| Operating expenses | $173.2M | $147.5M | $166.7M | $287.7M | $325.5M | $376.0M | $476.0M | $378.1M | $257.9M | $138.0M | $61.5M | $37.9M | $15.9M | $8.5M |
| Operating income | $23.5M | −$50.5M | −$46.3M | −$80.8M | −$264.5M | −$377.8M | −$286.3M | −$178.2M | −$76.7M | −$136.5M | −$61.5M | −$37.9M | −$15.9M | −$8.5M |
| Operating margin | 9.95% | −31.51% | −23.77% | −27.62% | −124.97% | −128.23% | −85.46% | −85.76% | −42.31% | −8,889.90% | — | — | — | — |
| EBITDA | $24.8M | −$13.0M | −$8.6M | −$79.1M | −$262.6M | −$375.8M | −$284.0M | −$177.3M | −$76.1M | −$136.2M | −$61.4M | −$37.9M | −$15.9M | −$8.5M |
| EBITDA margin | 10.49% | −8.10% | −4.43% | −27.05% | −124.06% | −127.53% | −84.79% | −85.33% | −41.97% | −8,870.62% | — | — | — | — |
| Net income | −$5.3M | −$69.4M | −$51.9M | −$94.2M | −$282.0M | −$384.8M | −$279.7M | −$143.6M | −$73.7M | −$135.7M | −$60.7M | −$37.0M | −$13.2M | −$8.2M |
| Net profit margin | −2.26% | −43.33% | −26.68% | −32.22% | −133.25% | −130.61% | −83.48% | −69.12% | −40.65% | −8,843.45% | — | — | — | — |
| Basic EPSper basic share | -$0.02 | -$0.33 | -$0.28 | -$0.52 | -$1.70 | -$2.78 | -$2.36 | -$2.47 | -$1.69 | -$3.60 | -$2.29 | -$8.04 | -$126.94 | -$27.82 |
| Diluted EPSper diluted share | -$0.02 | -$0.33 | -$0.28 | -$0.52 | -$1.70 | -$2.78 | -$2.36 | -$2.47 | -$1.69 | -$3.60 | -$2.29 | -$8.04 | -$126.94 | -$27.82 |
Owners
Reported shareholders
7.35%of listed shares
BlackRock, Inc.19.99M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 7.35%19.99M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.17%11.32M shares |
AQR CAPITAL MANAGEMENT LLC | 3.37%9.15M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.48%6.73M shares |
STATE STREET CORP | 1.98%5.39M shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 1.57%4.27M shares |
ACADIAN ASSET MANAGEMENT LLC | 1.47%4M shares |
Nantahala Capital Management, LLC | 1.47%4M shares |
GOLDMAN SACHS GROUP INC | 1.36%3.69M shares |
Butler John P. | ≈1.30%3.53M shares |
MILLENNIUM MANAGEMENT LLC | 1.18%3.2M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.93%2.53M shares |
TWO SIGMA INVESTMENTS, LP | 0.90%2.44M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.85%2.3M shares |
NORTHERN TRUST CORP | 0.80%2.16M shares |
VANGUARD FIDUCIARY TRUST CO | 0.70%1.91M shares |
FMR LLC | 0.69%1.87M shares |
Qube Research & Technologies Ltd | 0.65%1.78M shares |
CITADEL ADVISORS LLC | 0.63%1.72M shares |
UBS Group AG | 0.51%1.37M shares |
Percentages use 271.74M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 4, 2026Form 4 | Butler John P.CEO and President | BuyCommon Stock | 69.3K | $1.25 | $86.6K | 3.37M |
| Feb 2, 2026Form 4 · 10b5-1 | Rucci Carolyn M.SVP, Chief Legal Officer | SellCommon Stock | 27.5K | $1.39 | $38.3K | 588.4K |
| Feb 2, 2026Form 4 · 10b5-1 | Rucci Carolyn M.SVP, Chief Legal Officer | SellCommon Stock | 25.4K | $1.39 | $35.3K | 615.9K |
| Feb 2, 2026Form 4 · 10b5-1 | Rucci Carolyn M.SVP, Chief Legal Officer | SellCommon Stock | 16.8K | $1.39 | $23.4K | 641.3K |
| Feb 2, 2026Form 4 · 10b5-1 | Malabre Richard CSVP, Chief Accounting Officer | SellCommon Stock | 13.4K | $1.39 | $18.6K | 299.4K |
Community posts
Akebia doses the first patient in a rare-kidney-disease trial
Akebia ($AKBA) Therapeutics dosed the first patient in its Phase 2 basket trial of ebribafusp, an experimental treatment for rare complement-mediated kidney diseases. The study covers IgA nephropathy, lupus nephritis and C3 glomerulopathy. ...
